journal
MENU ▼
Read by QxMD icon Read
search

American Health & Drug Benefits

journal
https://www.readbyqxmd.com/read/29692880/healthcare-trends-for-2018
#1
F Randy Vogenberg, John Santilli
No abstract text is available yet for this article.
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692879/temporal-trends-in-survival-and-healthcare-costs-in-patients-with-multiple-myeloma-in-the-united-states
#2
Eric M Maiese, Kristin A Evans, Bong-Chul Chu, Debra E Irwin
Background: In recent years, the development of new therapies for multiple myeloma has improved the survival of patients, but newer treatments may also affect healthcare costs. To date, no real-world study has examined the concurrent changes in survival and total healthcare costs over time in patients with multiple myeloma. Objective: To examine the temporal changes in survival and healthcare costs among patients with multiple myeloma in the United States. Method: This retrospective claims-based cohort study is based on death files in the Truven Health MarketScan Research Commercial and Medicare Supplemental databases...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692878/newly-diagnosed-hepatitis-c-in-the-us-commercially-insured-population-before-and-after-the-2012-implementation-of-expanded-screening-guidelines
#3
Bruce S Pyenson, Gabriela Dieguez, Christine Ferro, Maushumi Mavinkurve, Yuri Sanchez Gonzalez
Background: In the United States in 2014, more than 3 million individuals were estimated to have chronic hepatitis C virus (HCV) infection, including many undiagnosed individuals. In 2012, the Centers for Disease Control and Prevention expanded its HCV testing recommendations to target all adults born between 1945 and 1965, in addition to at-risk individuals, which has led to an increase in newly diagnosed patients. Few studies have explored the medical cost or clinical status of patients who are newly diagnosed with HCV...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692877/predictors-of-transitioning-to-incident-chronic-opioid-therapy-among-working-age-adults-in-the-united-states
#4
J Douglas Thornton, Nilanjana Dwibedi, Virginia Scott, Charles D Ponte, Douglas Ziedonis, Nethra Sambamoorthi, Usha Sambamoorthi
Background: Opioids have been prescribed and used for chronic noncancer pain at prolific rates in the United States during the past 2 decades. Patients who transition to incident chronic opioid therapy are at increased risk for significant negative health consequences, including cardiovascular risk, endocrine disorders, opioid use disorder, and death. Objective: To identify the leading predictors associated with transitioning to incident chronic opioid therapy among working-age adults without cancer...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692876/still-at-it
#5
EDITORIAL
David B Nash
No abstract text is available yet for this article.
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403573/comparing-the-medicaid-retrospective-drug-utilization-review-program-cost-savings-methods-used-by-state-agencies
#6
REVIEW
Sergio I Prada
Background: The Medicaid Drug Utilization Review (DUR) program is a 2-phase process conducted by Medicaid state agencies. The first phase is a prospective DUR and involves electronically monitoring prescription drug claims to identify prescription-related problems, such as therapeutic duplication, contraindications, incorrect dosage, or duration of treatment. The second phase is a retrospective DUR and involves ongoing and periodic examinations of claims data to identify patterns of fraud, abuse, underutilization, drug-drug interaction, or medically unnecessary care, implementing corrective actions when needed...
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403572/amcp-nexus-2017-highlights
#7
(no author information available yet)
The following summaries represent a small sample of real-world, evidence-based information presented at AMCP Nexus 2017, October 16-19, 2017, in Dallas, TX.
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403571/the-effects-of-a-sitagliptin-formulary-restriction-program-on-diabetes-medication-use
#8
Yuexin Tang, Xingyue Huang, Jinan Liu, R Ravi Shankar, Michael L Ganz, Swapnil Rajpathak
Background: Health plans have responded to the many treatment options for type 2 diabetes mellitus by implementing formulary restriction policies, including step therapy, to control costs. Little is known about the impact of step therapy programs on antidiabetes medication use. Objective: To assess the impact of a sitagliptin step therapy program on antidiabetes medication use among sitagliptin users. Methods: Using pharmacy claims from the Symphony Health Solutions' Integrated Dataverse, we compared the use of sitagliptin and other antidiabetes medications by patients enrolled in a health plan (Plan A) that implemented a sitagliptin step therapy program on July 1, 2013, with the use by patients who were contemporaneously enrolled in 2 comparison plans-Plans B and C-without step therapy programs...
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403570/prospective-bundled-payments-in-a-changing-environment-the-experience-of-a-self-funded-state-sponsored-plan
#9
Frank H Lawler, Frank R Wilson, G Keith Smith, Lynn V Mitchell
Background: Healthcare reimbursement, which has traditionally been based on the quantity of services delivered, is currently moving toward value-based reimbursement-a system that addresses the quantity, quality, and cost of services. One such arrangement has been the evolution of bundled payments for a specific procedure or for an episode of care, paid prospectively or through post-hoc reconciliation. Objective: To evaluate the impact of instituting bundled payments that incorporate facility charges, physician fees, and all ancillary charges by the State of Oklahoma HealthChoice public employee insurance plan...
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403569/-alexa-refill-my-omeprazole
#10
EDITORIAL
David B Nash
No abstract text is available yet for this article.
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263775/the-value-of-pre-fda-approval-healthcare-economic-information-exchange-between-payers-and-drug-manufacturers
#11
Peter R Fendt, Brian Ung, F Randy Vogenberg
No abstract text is available yet for this article.
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263774/comparing-the-cost-of-treatment-with-octreotide-long-acting-release-versus-lanreotide-in-patients-with-metastatic-gastrointestinal-neuroendocrine-tumors
#12
Rajeev Ayyagari, Maureen Neary, Shang Li, Ariel Rokito, Hongbo Yang, Jipan Xie, Al B Benson
Background: The 2 somatostatin analogs currently recommended by the National Comprehensive Cancer Network for the treatment of gastrointestinal (GI) neuroendocrine tumors (NETs) include octreotide long-acting release (Sandostatin LAR) for injectable suspension and lanreotide (Somatuline Depot) injection for subcutaneous use. Objective: To estimate the costs to payers associated with 30-mg octreotide LAR and 120-mg lanreotide treatment among patients with metastatic GI-NETs...
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263773/major-cardiovascular-events-in-patients-with-gout-and-associated-cardiovascular-disease-or-heart-failure-and-chronic-kidney-disease-initiating-a-xanthine-oxidase-inhibitor
#13
JoAnne Foody, Robin S Turpin, Beni A Tidwell, Debra Lawrence, Kathy L Schulman
Background: Several observational studies and meta-analyses have suggested that treating hyperuricemia in patients with gout and moderate or severe chronic kidney disease (CKD) may improve renal and cardiovascular (CV) outcomes. Objective: To evaluate the impact of initiating allopurinol or febuxostat treatment on major CV events in patients with gout, preexisting CV disease (CVD) or heart failure (HF), and stage 3 or 4 CKD in a real-world setting. Methods: Patients with gout (aged >18 years) who initiated allopurinol or febuxostat treatment between 2009 and 2013 after a diagnosis of stage 3 or 4 CKD and CVD-including coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (PVD)-or HF were selected from the MarketScan databases...
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263772/-opioids-equal-heroin
#14
EDITORIAL
David B Nash
No abstract text is available yet for this article.
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263771/the-cost-of-hematopoietic-stem-cell-transplantation-in-the-united-states
#15
Michael S Broder, Tiffany P Quock, Eunice Chang, Sheila R Reddy, Rajni Agarwal-Hashmi, Sally Arai, Kathleen F Villa
Background: Hematopoietic stem-cell transplantation (HSCT) requires highly specialized, resource-intensive care. Myeloablative conditioning regimens used before HSCT generally require inpatient stays and are more intensive than other preparative regimens, and may therefore be more costly. Objective: To estimate the costs associated with inpatient HSCT according to the type of the conditioning regimen used and other potential contributors to the overall cost of the procedure...
October 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263770/economic-impact-of-increased-utilization-of-multivariate-assay-testing-to-guide-the-treatment-of-ovarian-cancer-implications-for-payers
#16
Burton S Brodsky, Gary M Owens, Dennis J Scotti, Keith A Needham, Christina L Cool
Background: Ovarian cancer is the eighth most common cancer among women, but ranks fifth in cancer-related causes of death, the majority of which are detected in late stages, after the cancer has metastasized. The CA125 test is the standard of care for assessing suspicious pelvic masses. However, the primary use of CA125 is to monitor treatment progress rather than to screen for disease, and its sensitivity is exceedingly low, unlike the multivariate assay OVA1. A cost-effective treatment of ovarian cancer requires early and accurate diagnosis of pelvic masses and reduced referrals of patients with benign tumors to a gynecologic oncologist...
October 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263769/trending-bio
#17
EDITORIAL
David B Nash
No abstract text is available yet for this article.
October 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975014/the-relative-burden-of-menopausal-and-postmenopausal-symptoms-versus-other-major-conditions-a-retrospective-analysis-of-the-medical-expenditure-panel-survey-data
#18
Annlouise R Assaf, Andrew G Bushmakin, Nina Joyce, Michael J Louie, Michael Flores, Margaret Moffatt
BACKGROUND: The direct costs associated with menopausal and postmenopausal symptoms (hereafter "menopausal symptoms") may include the costs of physician and emergency department visits, medications, laboratory testing, and the management of side effects. However, much remains unknown about the costs related to menopausal symptoms, including how they compare with the costs of other diseases that are common among menopausal women. OBJECTIVE: To compare the economic burden of menopausal symptoms with other select prevalent chronic conditions among a nationally representative sample of US menopausal women aged 45 to 65 years...
September 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975013/medication-adherence-treatment-patterns-and-dose-reduction-in-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-abiraterone-acetate-or-enzalutamide
#19
Ajay S Behl, Lorie A Ellis, Dominic Pilon, Yongling Xiao, Patrick Lefebvre
BACKGROUND: The efficacy of and overall survival associated with metastatic castration-resistant prostate cancer (CRPC) treatments rely on patients' consistent adherence to the recommended dosage regimens. OBJECTIVES: To evaluate treatment patterns and patient adherence to abiraterone acetate or enzalutamide therapy in real-world practice, and to examine the factors that may be associated with medication dose reduction in patients with metastatic CRPC. METHODS: Retrospective analyses were conducted using the Truven Health MarketScan research databases among patients with metastatic CRPC who initiated treatment with abiraterone acetate or enzalutamide between October 1, 2012, and December 31, 2014 (index date)...
September 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975012/costs-and-effectiveness-of-mindfulness-based-art-therapy-versus-standard-breast-cancer-support-group-for-women-with-cancer
#20
Katherine M Prioli, Laura T Pizzi, Kathryn M Kash, Andrew B Newberg, Anna Marie Morlino, Michael J Matthews, Daniel A Monti
BACKGROUND: The results of several studies have demonstrated that women and men with a cancer diagnosis benefit from interventions to reduce distress and improve quality of life (QOL). However, little is known about the costs and effectiveness of such interventions. Identifying a stress-reduction program that is low cost and effective is important for payers, employers, and healthcare professionals, as well as for patients with cancer. OBJECTIVE: To evaluate the direct costs and effectiveness of the mindfulness-based art therapy (MBAT) program compared with the cost and effectiveness of a breast cancer support group (BCSG)...
September 2017: American Health & Drug Benefits
journal
journal
48448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"